Health Point Inc. Advances Stem Cell Research


Posted January 20, 2015 by reginaldanderson

Clinical studies by Health Point Inc. continue to identify crucial stem cell discoveries to produce and stimulate new capillary (angiogenesis) and vessel (vasculogenesis) growth.

 
The company continues to refine the treatment of chronic lower limb ischemia. The principle behind this treatment is based on the stem cells ability to generate new vascular pathways. In most cases stem cell transplantation is performed locally, however if the condition indicate against surgery, larger doses of hematopoietic and mesenchymal progenitor cells may be applied.

Health Point Inc. is in the process of expanding research facilities needed to further the understanding of this breakthrough process. Funding for the expansion will be raised from this years IPO. The target price per share is $12, with 10 to 1 warrants also available.

Health Point Inc. (HPI) is a privately-owned company specializing in the development, manufacture and supply of stem cells for basic research and therapeutic development for the treatment of various diseases and conditions. The company utilizes what it calls Creative (stem cell-based) technology and other developed proprietary methods in the field of regenerative medicine that would enable drug discovery and life-changing therapies. More information can be found at healthpointincorporated.com.

Health Point Inc. is committed to deliver safe, effective and affordable stem cell therapies in a bench-to-bed approach, by nurturing cutting-edge research and clinical applications and by matching customer satisfaction in attaining the rejuvenating hope. Health Point Inc. strives to maintain scientific and ethical practices through a Quality Management System in accordance with accepted national and international norms. Health Point Inc. will accomplish this through dedicated efforts of its team to continually monitor and improve the effectiveness of the Quality Management System to excel and innovate thereby reflecting that we are truly pro-Life.

The information contained in this release is provided on an errors and omissions excepted basis. No statements contained within are to be construed as an offer for sale of share capital or any other offer contrary to securities law. Information is current at time of publishing. Health Point Inc. cannot be held responsible for out of date or changing information. It is the responsibility of the reader to seek out up to date company information at healthpointincorporated.com and other sources before making any material decisions.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Reginald Anderson
Phone 85281930750
Business Address 15/F Millennium City 5 (APM)
418 Kwun Tong Rd Central, Hong Kong
Country China
Categories Business
Tags health , investment , manufacture , research , stem cells , supply
Last Updated January 20, 2015